InsidersTradesSigma
Follow the Castle Biosciences INC share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Castle Biosciences INC has recorded 473 public disclosures. Market capitalisation: €1.1bn. The latest transaction was reported on 27 August 2026 (Cession). Among the most active insiders: MAETZOLD DEREK J. All data is openly available.
Castle Biosciences INC, listed on XNAS in the Healthcare & Pharma sector, reported a total of 93 insider trading declarations over the past 90 days. The total amount from insider selling reached approximately 5,812,560 euros, with no purchases recorded. The top insiders involved in selling include Derek J. Maetzold, the President and Chief Executive Officer, with sales totaling around 2,797,395 euros across 75 declarations. Kristen M. Oelschlager, the Chief Operating Officer, reported sales of about 1,123,563 euros from 9 declarations. Tobin W. Juvenal, the Chief Commercial Officer, had sales totaling approximately 842,172 euros from 7 declarations. Notable recent sales include Frank Stokes, the Chief Financial Officer, who sold approximately 642,519 euros on August 18, 2026, and Kristen Oelschlager, who sold about 532,269 euros on June 16, 2026.
Auto-generated summary, refreshed daily.Updated 1d ago
473
Insider Decl.
n/a
Thresholds
€68,143
3 ops.
Buy Volume
€32m
343 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Castle Biosciences INC Strong Buy (bullish), based on 9 analysts. Average price target: US$44.00.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,547 of 29,024 companies
40.4
score / 100
Value40
Quality41
FCF yld2.8%
Earn yld-2.4%
EV/EBITDA·
ROE-4.2%
Gross mgn79%
Net mgn-7.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations473 total
9,050 shares@ US$35.04Common StockSEC:0001628280-26-059272:0
12,218 shares@ US$33.6870.038% mcap8.7% of flowCommon StockSEC:0001628280-26-059091:0
7,161 shares@ US$34.2630.023% mcap5.2% of flowCommon StockSEC:0001628280-26-059091:1
5,223 shares@ US$34.6390.017% mcap3.8% of flowCommon StockSEC:0001628280-26-059091:2
1,730 shares@ US$29.590.0056% mcap2.6% of flowCommon StockSEC:0001628280-26-057949:0
1,100 shares@ US$30.020.0036% mcap0.2% of flowCommon StockSEC:0001628280-26-057642:1
1,100 shares@ US$2.390.0003% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:0
2,714 shares@ US$30.020.0089% mcap0.4% of flowCommon StockSEC:0001628280-26-057642:2
2,306 shares@ US$30.020.0076% mcap0.4% of flowCommon StockSEC:0001628280-26-057642:3
278 shares@ US$30.020.0009% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:4
278 shares@ US$30.020.0009% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:5
278 shares@ US$30.020.0009% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:6
278 shares@ US$30.020.0009% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:7
24,908 shares@ US$29.770.081% mcap36.7% of flowCommon StockSEC:0001628280-26-057644:0
2,866 shares@ US$30.7880.0093% mcap0.5% of flowCommon StockSEC:0001628280-26-054334:3
556 shares@ US$30.6810.0018% mcap0.1% of flowCommon StockSEC:0001628280-26-054334:9
8,421 shares@ US$30.7880.027% mcap1.4% of flowCommon StockSEC:0001628280-26-054334:1
4,063 shares@ US$31.3360.013% mcap0.7% of flowCommon StockSEC:0001628280-26-054334:6
2,546 shares@ US$30.6810.0082% mcap0.4% of flowCommon StockSEC:0001628280-26-054334:8
473 shares@ US$30.6810.0015% mcap0.1% of flowCommon StockSEC:0001628280-26-054334:10
11,935 shares@ US$31.3360.039% mcap2.1% of flowCommon StockSEC:0001628280-26-054334:4
1,301 shares@ US$38.392.6% of flowCommon StockSEC:0001628280-26-054338:0
4,782 shares@ US$31.3360.016% mcap0.8% of flowCommon StockSEC:0001628280-26-054334:5
20,356 shares@ US$2.390.0051% mcap0.3% of flowCommon StockSEC:0001628280-26-054334:0
3,374 shares@ US$30.7880.011% mcap0.6% of flowCommon StockSEC:0001628280-26-054334:2
25 of 473 declarations
About Castle Biosciences INC
Castle Biosciences, Inc. (NASDAQ: CSTL) is a U.S.-based molecular diagnostics company headquartered in Friendswood, Texas, in the United States. For French-speaking investors, it is a healthcare specialist focused on prognostic and diagnostic tests designed to improve treatment decisions in areas with meaningful unmet medical need. The company was founded in 2007 by Derek Maetzold, who remains its President and Chief Executive Officer. Its business model is built around proprietary laboratory-developed tests that aim to deliver clinically actionable information derived from tumor biology and related molecular signatures. Castle’s legacy and still-core franchise is dermatologic oncology. Its portfolio includes DecisionDx-Melanoma, DecisionDx-SCC, and MyPath Melanoma, which are intended to help clinicians refine risk assessment for patients with cutaneous melanoma, cutaneous squamous cell carcinoma, and suspicious pigmented lesions. The company has also expanded beyond skin cancer into gastroenterology through TissueCypher, a test used to identify Barrett’s esophagus patients at higher risk of progression to esophageal cancer. More recently, Castle launched AdvanceAD-Tx to support systemic treatment decision-making in moderate-to-severe atopic dermatitis, underscoring a strategy of broadening its franchise into adjacent high-value disease areas. From a competitive standpoint, Castle positions itself as a focused specialist in high-utility molecular testing, differentiated by clinical evidence and physician adoption rather than scale alone. The company emphasizes a substantial body of peer-reviewed publications and accumulating real-world data that support the clinical validity and utility of its tests versus conventional pathology or staging approaches. Operationally, its footprint remains U.S.-centric, with clinical laboratories in Phoenix and Pittsburgh alongside its new corporate headquarters in Friendswood. That setup supports both commercialization and laboratory execution while keeping the company close to U.S. clinicians and payer dynamics. Recent developments highlight improving momentum. In the first quarter of 2026, Castle reported revenue of $83.7 million and raised full-year 2026 revenue guidance to $345–355 million, reflecting strong performance from its core growth drivers, DecisionDx-Melanoma and TissueCypher. The company also announced the grand opening of its new headquarters in Friendswood in March 2026, a sign of long-term investment in infrastructure and capacity. For investors, CSTL offers exposure to a NASDAQ-listed U.S. diagnostics platform with specialized growth franchises, but it also carries the usual risks tied to reimbursement, regulatory scrutiny, and the need to continually prove clinical and economic value.
